Jiangsu Bioperfectus Technologies Co Ltd (688399) - Total Liabilities
Based on the latest financial reports, Jiangsu Bioperfectus Technologies Co Ltd (688399) has total liabilities worth CN¥681.04 Million CNY (≈ $99.66 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Jiangsu Bioperfectus Technologies Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Jiangsu Bioperfectus Technologies Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Jiangsu Bioperfectus Technologies Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 688399 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Jiangsu Bioperfectus Technologies Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Bioperfectus Technologies Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
USA | $5.84 Million |
|
Jash Engineering Limited
NSE:JASH
|
India | Rs3.27 Billion |
|
Advancetek Enterprise Co Ltd
TW:1442
|
Taiwan | NT$6.45 Billion |
|
Qibu Co Ltd
SHG:603557
|
China | CN¥624.41 Million |
|
Agencia Comercial Spirits Ltd Class A Ordinary Shares
NASDAQ:AGCC
|
USA | $18.35 Million |
|
Cion Investment Corp
NYSE:CION
|
USA | $1.18 Billion |
|
Sysgration Ltd
TWO:5309
|
Taiwan | NT$1.54 Billion |
|
Guangzhou Shangpin Home Collection Co Ltd
SHE:300616
|
China | CN¥3.51 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Jiangsu Bioperfectus Technologies Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688399 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Bioperfectus Technologies Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Bioperfectus Technologies Co Ltd (2016–2024)
The table below shows the annual total liabilities of Jiangsu Bioperfectus Technologies Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥489.32 Million ≈ $71.60 Million |
-2.39% |
| 2023-12-31 | CN¥501.31 Million ≈ $73.36 Million |
-54.95% |
| 2022-12-31 | CN¥1.11 Billion ≈ $162.84 Million |
+15.57% |
| 2021-12-31 | CN¥962.89 Million ≈ $140.90 Million |
+57.03% |
| 2020-12-31 | CN¥613.18 Million ≈ $89.73 Million |
+359.06% |
| 2019-12-31 | CN¥133.57 Million ≈ $19.55 Million |
+86.91% |
| 2018-12-31 | CN¥71.46 Million ≈ $10.46 Million |
+41.88% |
| 2017-12-31 | CN¥50.37 Million ≈ $7.37 Million |
+47.74% |
| 2016-12-31 | CN¥34.09 Million ≈ $4.99 Million |
-- |
About Jiangsu Bioperfectus Technologies Co Ltd
Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. The company offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. It also provides HPV and cervical cancer testing services, respiratory infection detection solution, … Read more